Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  The Lancet Oncology

• Publication date

  2003-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S1470-2045(03)01034-9PMID 12681266
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.

  2002cited by this paper
• Ethanol and LPS modulate NF-kappaB activation, inducible NO synthase and COX-2 gene expression in rat liver cells in vivo.

  2002cited by this paper
• Reduction in cytochrome P-450 enzyme expression is associated with repression of CAR (constitutive androstane receptor) and PXR (pregnane X receptor) in mouse liver during the acute phase response.

  2002cited by this paper
• Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: Correlation with stage and performance status

  2002cited by this paper
• Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response

  2002cited by this paper
• Differential effect of IFNalpha-2b on the cytochrome P450 enzyme system: a potential basis of IFN toxicity and its modulation by other drugs.

  2002cited by this paper
• The role of C-reactive protein as a prognostic indicator in advanced cancer

  2002cited by this paper
• Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancer

  2001cited by this paper
• Drug‐disease interactions: reduced β‐adrenergic and potassium channel antagonist activities of sotalol in the presence of acute and chronic inflammatory conditions in the rat

  2001cited by this paper
• Inflammation and cancer: back to Virchow?

  2001cited by this paper
• Nuclear factor-kappa B is upregulated in colorectal cancer.

  2001cited by this paper
• Inhibition of NF-kappa B with proteasome inhibitors enhances apoptosis in human lung adenocarcinoma cells in vitro.

  2001cited by this paper
• Nuclear factor-κB is upregulated in colorectal cancer

  2001cited by this paper
• Cytokine-mediated modulation of cisplatin sensitivity in ovarian cancer cells

  2001cited by this paper
• Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site.

  2000cited by this paper
• Inhibition of NF-kappaB sensitizes non-small cell lung cancer cells to chemotherapy-induced apoptosis.

  2000cited by this paper
• Nuclear factor-kappa B, cancer, and apoptosis.

  2000cited by this paper
• Soluble Cytokine Levels Correlate with the Activity and Clinical Stage of Hodgkin's Disease at Diagnosis

  2000cited by this paper
• Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes.

  2000cited by this paper
• A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer.

  2000cited by this paper
• Optimizing the erythromycin breath test for use in cancer patients.

  2000cited by this paper
• Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

  2000cited by this paper
• Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel.

  2000cited by this paper
• Higher Incidence of Elevated Body Temperature or Increased C‐Reactive Protein Level in Asthmatic Children Showing Transient Reduction of Theophylline Metabolism

  2000cited by this paper
• The influence of interferon-alpha on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite in patients with multiple myeloma.

  1999cited by this paper
• The influence of interferon‐α on the pharmacokinetics of cyclophosphamide and its 4‐hydroxy metabolite in patients with multiple myeloma

  1999cited by this paper
• Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma.

  1999cited by this paper
• The Effect of High Dose Endotoxin on CYP3A2 Expression in the Rat

  1998cited by this paper
• Down-regulation of Cytochrome P450 1A1 Gene Promoter by Oxidative Stress

  1998cited by this paper
• Serum levels of interleukin-6 as a prognostic factor in advanced non-small cell lung cancer.

  1998cited by this paper
• Predicting Effective Drug Concentrations for Individual Patients

  1998cited by this paper
• Cytokines and chemokines in HIV infection: implications for therapy.

  1998cited by this paper
• Soluble interleukin‐2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma

  1997cited by this paper
• Regulation of cytochromes P450 during inflammation and infection.

  1997cited by this paper
• The role of nuclear factor-kappa B in cytokine gene regulation.

  1997cited by this paper
• The importance of context in cytokine action.

  1997cited by this paper
• N‐acetylation among HIV‐positive patients and patients with AIDS: When is fast, fast and slow, slow?

  1997cited by this paper
• Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl‐2

  1997cited by this paper
• Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women.

  1997cited by this paper
• Cytokine function: a study in biologic diversity.

  1996cited by this paper
• Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study.

  1996cited by this paper
• Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

  1996cited by this paper
• Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.

  1995cited by this paper
• Sexual Health Promotion in General Practice

  1995cited by this paper
• Immunol. Cell Biol.

  1995cited by this paper
• Acute phase proteins and recombinant IL‐2 therapy: prediction of response and survival in patients with colorectal cancer

  1995cited by this paper
• The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions.

  1995cited by this paper
• Acute‐phase response, interleukin‐6, and alteration of cyclosporine pharmacokinetics

  1994cited by this paper
• Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism.

  1994cited by this paper
• Interferon‐alpha up‐regulates bcl‐2 expression and protects B‐CLL cells from apoptosis in vitro and in vivo

  1994cited by this paper
• Induction of metallothionein and stomatin by interleukin-6 and glucocorticoids in a human amniotic cell line.

  1994cited by this paper
• Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients.

  1994cited by this paper
• Suppression of cytochrome P450IA1 by interleukin-6 in human HepG2 hepatoma cells.

  1994cited by this paper
• Interferon suppresses erythromycin metabolism in rats and human subjects

  1993cited by this paper
• Effects of interferon-alpha monotherapy on hepatic drug metabolism in cancer patients.

  1993cited by this paper
• Interleukin 2 therapy in cancer: identification of responders.

  1992cited by this paper
• Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

  1992cited by this paper
• Heme oxygenase is a positive acute-phase reactant in human Hep3B hepatoma cells.

  1992cited by this paper
• Characterization of human cytochrome P450 enzymes

  1992cited by this paper
• Interleukin 6 regulates metallothionein gene expression and zinc metabolism in hepatocyte monolayer cultures.

  1990cited by this paper
• Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients.

  1989cited by this paper
• Effects of influenza virus vaccine on hepatic drug metabolism

  1985cited by this paper
• A prognostic inflammatory and nutritional index scoring critically ill patients.

  1985cited by this paper
• Alterations in hepatic heme and cytochrome P-450 metabolism in Murphy-Sturm lymphosarcoma-bearing rats. Implications for drug metabolism.

  1984cited by this paper
• Biochemical basis for impaired drug metabolism in tumor-bearing rats. Evidence for altered regulation of hepatic microsomal hemeprotein synthesis.

  1982cited by this paper
• Alterations in hepatic and splenic microsomal electron transport system components, drug metabolism, heme oxygenase activity, and cytochrome P-450 turnover in Murphy-Sturm lymphosarcoma-bearing rats.

  1982cited by this paper
• Drug metabolism in rats bearing a pituitary mammotropic tumor.

  1979cited by this paper
• Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation.

  1977cited by this paper
• Plasma protein binding of basic drugs. I. Selective displacement from alpha 1-acid glycoprotein by tris(2-butoxyethyl) phosphate.

  1977cited by this paper
• Plasma protein binding of basic drugs

  1977cited by this paper
• Prolonged metabolism of pentobarbital in isolated perfused liver of tumor bearing rats.

  1972cited by this paper
• Evidence That Inhibition of Hepatic Drug Oxidation by Tumors is Mediated by a Circulating Humor 1

  1972cited by this paper
• Barbiturate metabolism as affected by neoplastic disease.

  1971cited by this paper
• Impairment of drug metabolism in tumor-bearing animals

  1971cited by this paper
• Impairement of drug metabolism in tumor-bearing animals.

  1971cited by this paper
• Effect of toxohormone on microsomal cytochromes and hydroxylating systems of rat liver.

  1969cited by this paper
• Metabolic fate of zoxazolamine in tumor bearing rats.

  1969cited by this paper
• Prolonged effect of pentobarbital in tumor bearing rats.

  1968cited by this paper
• An investigation of the decrease in the metabolism of hexobarbital, aminopyrine and p-nitrobenzoic acid by liver from rats bearing a pituitary mammotropic tumor.

  1968cited by this paper
• Drug metabolism in tumor-bearing rats. I. Activities of NADPH-linked electron transport and drug-metabolizing enzyme systems in liver microsomes of tumor-bearing rats.

  1968cited by this paper
• Hepatic Drug Metabolism after Phenobarbital or 3-Methylcholanthrene Pretreatment of Rats Bearing a Pituitary Tumor

  1968cited by this paper
• Drug metabolism in tumor-bearing rats. II. In vivo metabolisms and effects of drugs in tumor-bearing rats.

  1968cited by this paper

• A population pharmacokinetic model for early follow-up dosing of tacrolimus in Tunisian kidney transplant recipients.

  2026cites this paper
• Model for predicting completion of chemoradiotherapy in patients with unresectable stage III non-small cell lung cancer: Analysis of pooled data from a clinical trial database

  2026cites this paper
• Relationship between Ki-67 and P53 immunohistochemical expression and osteosarcoma chemotherapy sensitivity and long-term prognosis.

  2025cites this paper
• Targeted drug monitoring in oncology for personalized treatment with use of next generation analytics

  2025cites this paper
• Muscle Loss During First‐Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity

  2025cites this paper
• Maternal MitoQ Treatment Is Protective Against Programmed Alterations in CYP Activity Due to Antenatal Dexamethasone

  2025cites this paper
• Duration of aromatase inhibitor use and long-term cardiovascular risk in breast cancer survivors

  2025cites this paper
• Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer

  2025cites this paper
• Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward

  2025cites this paper
• Risk of cardiovascular mortality in patients with gastric cancer

  2025cites this paper
• Epidemiology and Risk Determinants of Drug‐Induced Liver Injury: Current Knowledge and Future Research Needs

  2024cites this paper
• Hydroxychloroquine in SARS-CoV-2 infection: Understanding the misadventure

  2024cites this paper
• Lung cancer and risk of cardiovascular mortality

  2024cites this paper
• Single anthocyanins effectiveness modulating inflammation markers in obesity: dosage and matrix composition analysis

  2023cites this paper
• Mirvetuximab soravtansine in ovarian cancer therapy: expert opinion on pharmacological considerations

  2023cites this paper
• Gallic Acid Attenuates Cardiovascular and Hematological Complications in Vincristine Treatment via Hydroxyl Radical Scavenging and Endogenous Antioxidant Stimulation in Male Wistar Rats

  2023cites this paper
• Associations of plasma aprepitant and its N-dealkylated metabolite with cachexia status and clinical responses in head and neck cancer patients

  2023cites this paper
• In Search of the Perfect Thrombosis and Bleeding-Associated Cancer Scale

  2023cites this paper
• A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations

  2023cites this paper
• Unraveling the Effects of Acute Inflammation on Pharmacokinetics: A Model-Based Analysis Focusing on Renal Glomerular Filtration Rate and Cytochrome P450 3A4-Mediated Metabolism

  2023cites this paper
• Evaluation of therapeutics' drug monitoring during cancer chemotherapy: A review

  2023cites this paper
• Geriatric nutritional risk index as a predictor of prognosis in hematologic malignancies: a systematic review and meta-analysis

  2023cites this paper
• Evaluation of Intravenous Phenobarbital Pharmacokinetics in Critically Ill Patients With Brain Injury

  2022cites this paper
• Disrupting circadian rhythms promotes cancer-induced inflammation in mice

  2022cites this paper
• Establishment and Characterization of Novel Human Intestinal In Vitro Models for Absorption and First-Pass Metabolism Studies

  2022cites this paper
• Clozapin aus Sicht des Projekts "Arzneimittelsicherheit in der Psychiatrie"

  2022cites this paper
• Comparing Effects of Polypharmacy on Inflammatory Profiles in Older Adults and Mice: Implications for Translational Aging Research

  2022cites this paper
• Prognostic impacts of categorized postoperative complications in surgery for gastric cancer.

  2022cites this paper
• Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

  2022cites this paper
• Pretreatment Platelet Count and Neutrophil/Lymphocyte Ratio Are Predictive Markers for Carboplatin Plus Pemetrexed Therapy-induced Thrombocytopenia

  2021cites this paper
• Alpha-1 Acid Glycoprotein as a Biomarker for Subclinical Illness and Altered Drug Binding in Rats.

  2021cites this paper
• Pretreatment Inflammatory-Nutritional Biomarkers Predict Responses to Neoadjuvant Chemoradiotherapy and Survival in Locally Advanced Rectal Cancer

  2021cites this paper
• Pyomyositis in a Patient Undergoing Chemotherapy for Gastric Cancer: A Case Report and Literature Review

  2021cites this paper
• Drug-drug Interactions between COVID-19 Treatments and Antidepressants, Mood Stabilizers/Anticonvulsants, and Benzodiazepines: Integrated Evidence from 3 Databases

  2021cites this paper
• Involvement of the Parathyroid Hormone-Related Protein on Changes in the CYP3A Expression in Cancer Cachexia.

  2021cites this paper
• Therapeutic Drug Monitoring of Second- and Third-Generation Antipsychotic Drugs—Influence of Smoking Behavior and Inflammation on Pharmacokinetics

  2021cites this paper
• CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions

  2020cites this paper
• The impact of intrauterine growth restriction on cytochrome P450 enzyme expression and activity.

  2020cites this paper
• Associations between Pregnane X Receptor and Breast Cancer Growth and Progression

  2020influential citation
• Inability of Current Dosing to Achieve Carboplatin Therapeutic Targets in People with Advanced Non-Small Cell Lung Cancer: Impact of Systemic Inflammation on Carboplatin Exposure and Clinical Outcomes

  2020cites this paper
• What is the current state of thrombosis treatment and prevention in cancer patients?

  2020cites this paper
• Modified Glasgow Prognostic Score, Prognostic Nutritional Index and ECOG Performance Score Predicts Survival Better than Sarcopenia, Cachexia and Some Inflammatory Indices in Metastatic Gastric Cancer

  2020cites this paper
• Disrupted hepatic pentose phosphate pathway directly participates in and indirectly promotes CYP3A reduction: A new strategy for CYP3A‐mediated drug hepatotoxicity

  2020cites this paper
• Dynamic Alteration of Neutrophil-to-Lymphocyte Ratio over Treatment Trajectory is Associated with Survival in Esophageal Adenocarcinoma

  2020cites this paper
• Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology

  2020cites this paper
• Low Levels of High-density Lipoprotein in Patients with Pediatric Cancer at Diagnosis

  2020cites this paper
• Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics

  2020cites this paper
• A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2− Primary Breast Cancer

  2020cites this paper
• The Role of CYP450 Drug Metabolism in Precision Cardio-Oncology

  2020cites this paper
• The Relationship of SUV Value in PET-CT with Tumor Differentiation and Tumor Markers in Gastric Cancer.

  2020cites this paper
• Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer.

  2020cites this paper
• Roles of Hepatic Drug Transporters in Drug Disposition and Liver Toxicity.

  2019cites this paper
• Model based dosing of tacrolimus after renal transplantation

  2019cites this paper
• Hepatic and intestinal biotransformation gene expression and drug disposition in a dextran sulfate sodium-induced colitis mouse model

  2019cites this paper
• Recent advances in the treatment and prevention of venous thromboembolism in cancer patients: role of the direct oral anticoagulants and their unique challenges

  2019cites this paper
• Altered cytochrome 2E1 and 3A P450‐dependent drug metabolism in advanced ovarian cancer correlates to tumour‐associated inflammation

  2019cites this paper
• MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation.

  2019cites this paper
• A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients

  2019cites this paper
• The Influence of Proinflammatory Cytokines on Voriconazole Trough Concentration in Patients With Different Forms of Hematologic Disorders

  2019cites this paper
• Isoform-Dependent Changes in Cytochrome P450-Mediated Drug Metabolism after Portal Vein Ligation in the Rat

  2018cites this paper
• Local Skin Inflammation in Cutaneous Leishmaniasis as a Source of Variable Pharmacokinetics and Therapeutic Efficacy of Liposomal Amphotericin B

  2018cites this paper
• Local skin inflammation in cutaneous leishmaniasis as a source of variable 1 pharmacokinetics and therapeutic efficacy of liposomal amphotericin B 2

  2018cites this paper
• Expression of Hepatic Cytochrome P450 Drug Metabolizing Enzymes in Diabetes and Diabetic Nephropathy

  2018cites this paper
• Clinical pharmacology considerations for children supported with ventricular assist devices

  2018cites this paper
• Not only tumor but also therapy heterogeneity.

  2018cites this paper
• Insilico Investigation of CYP 1 A 1 Mediated Pathway Contribution in Liver Hepatocellular Carcinoma : A Drug Discovery Approach

  2018cites this paper
• Glasgow Prognostic Score is superior to ECOG PS as a prognostic factor in patients with gastric cancer with peritoneal seeding.

  2018cites this paper
• Impact of CYP genotype and inflammatory markers on the plasma concentrations of tramadol and its demethylated metabolites and drug tolerability in cancer patients

  2018cites this paper
• Drug Dosing at the End of Life: a Pharmacometric Approach

  2018influential citation
• Pharmacokinetic variability of anticoagulants in patients with cancer-associated thrombosis: Clinical consequences.

  2018cites this paper
• Abilities of Pre- and Postoperative High-Sensitivity C-Reactive Protein Levels to Predict 90-Day Mortality After Surgery for Abdominal and Thoracic Cancers

  2018cites this paper
• Evaluation and Management of Postoperative Fever in the Gynecologic Patient

  2018cites this paper
• High-Fat Diets Alter the Modulatory Effects of Xenobiotics on Cytochrome P450 Activities.

  2018cites this paper
• Inflammation Investigated as a Source of Pharmacokinetic Variability of Atazanavir in AIDS Clinical Trials Group Protocol A5224s

  2018cites this paper
• CYP3A4 Activity is Markedly Lower in Patients with Crohn's Disease

  2017cites this paper
• Altered gene expression of hepatic cytochrome P450 in a rat model of intermittent hypoxia with emphysema.

  2017cites this paper
• Modeling Sex Differences in Pharmacokinetics, Pharmacodynamics, and Disease Progression Effects of Naproxen in Rats with Collagen-Induced Arthritis

  2017cites this paper
• Hepatic Cyp1a2 Expression Reduction during Inflammation Elicited in a Rat Model of Intermittent Hypoxia

  2017cites this paper
• Effect of Disease-Related Changes in Plasma Albumin on the Pharmacokinetics of Naproxen in Male and Female Arthritic Rats

  2017cites this paper
• Inflammation and pharmacokinetics: potential implications for HIV-infection

  2017cites this paper
• Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients

  2017cites this paper
• Pharmacokinetics, pharmacodynamics and pharmacogenetics associated with nonsteroidal anti-inflammatory drugs and opioids in pediatric cancer patients

  2017cites this paper
• Drug metabolism and liver disease: a drug–gene–environment interaction

  2017cites this paper
• Management of Cancer in the Older Age Person: An Approach to Complex Medical Decisions.

  2017cites this paper
• Effets du diabète de type 2 sur l’expression et l’activité des cytochromes P450 hépatiques et extra-hépatiques chez la souris C57BL/6 sous une diète riche en gras

  2017cites this paper
• Hypoalbuminaemia and decreased midazolam clearance in terminally ill adult patients, an inflammatory effect?

  2017cites this paper
• Impact of nanomedicine on hepatic cytochrome P450 3A4 activity: things to consider during pre-clinical and clinical studies

  2017cites this paper
• Plasma vemurafenib exposure and pre-treatment hepatocyte growth factor level are two factors contributing to the early peripheral lymphocytes depletion in BRAF-mutated melanoma patients.

  2016cites this paper
• Systemic inflammation is an independent predictive marker of clinical outcomes in mucosal squamous cell carcinoma of the head and neck in oropharyngeal and non-oropharyngeal patients

  2016cites this paper
• Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics

  2016cites this paper
• Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations

  2016cites this paper
• The Glasgow Prognostic Score Predicts Response to Chemotherapy in Patients with Metastatic Breast Cancer

  2016cites this paper
• Pharmacokinetic considerations and recommendations in palliative care, with focus on morphine, midazolam and haloperidol

  2016cites this paper
• Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome

  2016cites this paper
• Relationships between oxycodone pharmacokinetics, central symptoms, and serum interleukin-6 in cachectic cancer patients

  2016cites this paper
• Studies of drug disposition in hemodialysis patients : impact of genetics, inflammation and vitamin D

  2016cites this paper
• Glucocorticoid receptor contributes to the altered expression of hepatic cytochrome P450 upon cigarette smoking.

  2016cites this paper
• Simulation and optimization of logical and kinetic biochemical models

  2016cites this paper
• Coordinating Role of RXRα in Downregulating Hepatic Detoxification during Inflammation Revealed by Fuzzy-Logic Modeling

  2016cites this paper
• A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer

  2016cites this paper